Compare
Benchmarked on the axes the guidelines say drive choice — tolerability first. Every cell cited.
| Dimension | LB-102 | Quetiapine | Ziprasidone | Pimavanserin | Clozapine | Valaciclovir |
|---|---|---|---|---|---|---|
US status | Investigational | Approved | Approved | Approved | Approved | Investigational |
Modality | small molecule | small molecule | small molecule | small molecule | small molecule | small molecule |
FDA class | — | — | Atypical Antipsychotic [EPC] | — | Atypical Antipsychotic [EPC] | — |
Protection | 2037 (issued) | — | — | 2039 | 2028 | — |
Label expansions regulatory velocity | — | — | — | — | — | — |
Weight Metabolic FAERS within-drug share · lower is better | — | 6.5% | 15.0% | — | 1.8%✓ best | — |
Prolactin FAERS within-drug share · lower is better | — | — | 1.0%✓ best | — | — | — |
Sedation FAERS within-drug share · lower is better | — | 5.2% | 5.3% | 3.6% | 2.8%✓ best | — |
FAERS shares are spontaneous-reporting signals, not incidence rates. “Best” marks the lowest reported share on that axis among the compared set.